Diabetes mellitus and the risk of Alzheimer's disease: A nationwide population-based study

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Huang, Chin Chou ^a,b   Chung, Chia Min ^d,e   Leu, Hsin Bang ^a,b   Lin, Liang Yu ^a,b   Chiu, Chun Chih ^a,b   Hsu, Chien Yi ^a,b   Chiang, Chia Hung ^b,c   Huang, Po Hsun ^a,b   Chen, Tzeng Ji ^a,b   Lin, Shing Jong ^a,b   Chen, Jaw Wen ^a,b   Chan, Wan Leong ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c Zhudong Veterans Hospital   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; GLITAZONE DERIVATIVE; INSULIN; INSULIN DERIVATIVE; METFORMIN; SULFONYLUREA;

ADULT; AGE DISTRIBUTION; ALZHEIMER DISEASE; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MONOTHERAPY; POPULATION BASED CASE CONTROL STUDY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; URBANIZATION;

AGED; ALZHEIMER DISEASE; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS;

EID: 84899414414     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087095     Document Type: Article

References (37)

1. Roberts JS, Tersegno SM (2010) Estimating and disclosing the risk of developing Alzheimer's disease: challenges, controversies and future directions. Future Neurol 5: 501-517.
2. Hurd MD, Martorell P, Delavande A, Mullen KJ, Langa KM (2013) Monetary costs of dementia in the United States. N Engl J Med 368: 1326-1334.
3. Maiorini AF, Gaunt MJ, Jacobsen TM, McKay AE, Waldman LD, et al. (2002) Potential novel targets for Alzheimer pharmacotherapy: I. secretases. J Clin Pharm Ther 27: 169-183. (Pubitemid 34748141)
4. Thies W, Bleiler L (2011) 2011 Alzheimer's disease facts and figures. Alzheimers Dement 7: 208-244.
5. Wolfson C, Wolfson DB, Asgharian M, M'Lan CE, Ostbye T, et al Clinical Progression of Dementia Study Group (2001) A reevaluation of the duration of survival after the onset of dementia. N Engl J Med 344: 1111-1116. (Pubitemid 32285231)
6. Treatment Guideline Subcommittee of the Taiwan Headache Society (2011) Guidelines for the medical treatment of patients with Alzheimer's disease. Acta Neurol Taiwan 20: 85-100.
7. Daviglus ML, Plassman BL, Pirzada A, Bell CC, Bowen PE, et al. (2011) Risk Factors and Preventive Interventions for Alzheimer Disease: State of the Science. Arch Neurol 68: 1185-1190.
8. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, et al. (1999) Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 53: 1937-1942.
9. Xu WL, Qiu CX, Wahlin A, Winblad B, Fratiglioni L (2004) Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 63: 1181-1186. (Pubitemid 39350014)
10. Schrijvers EM, Witteman JC, Sijbrands EJ, Hofman A, Koudstaal PJ, et al. (2010) Insulin metabolism and the risk of Alzheimer disease: the Rotterdam Study. Neurology 75: 1982-1987.
11. MacKnight C, Rockwood K, Awalt E, McDowell I (2002) Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord 14: 77-83. (Pubitemid 36152948)
12. Akomolafe A, Beiser A, Meigs JB, Au R, Green RC, et al. (2006) Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. Arch Neurol 63: 1551-1555. (Pubitemid 44748797)
13. Euser SM, Sattar N, Witteman JC, Bollen EL, Sijbrands EJ, et al for the PROSPER and Rotterdam Study. (2010) A prospective analysis of elevated fasting glucose levels and cognitive function in older people: results from PROSPER and the Rotterdam Study. Diabetes 59: 1601-1607.
14. Bureau of National Health Insurance (2001) National Health Insurance Annual Statistical Report. Taipei, Taiwan: Bureau of National Health Insurance; 2002.
15. Chiang CW, Chen CY, Chiu HF, Wu HL, Yang CY (2007) Trends in the use of antihypertensive drugs by outpatients with diabetes in Taiwan, 1997-2003. Pharmacoepidemiol Drug Saf 16: 412-421.
16. Chen HF, Ho CA, Li CY (2008) Increased risks of hip fracture in diabetic patients of Taiwan: a population-based study. Diabetes Care 31: 75-80.
17. Sohn MW, Lee TA, Stuck RM, Frykberg RG, Budiman-Mak E (2009) Mortality risk of Charcot arthropathy compared with that of diabetic foot ulcer and diabetes alone. Diabetes Care 32: 816-821.
18. WHO Collaborating Center for Drug Statistics Methodology (2003) ATC Index with DDDs 2003. WHO: Oslo.
19. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
20. McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34: 939-944. (Pubitemid 14076461)
21. American Psychiatric Association (2000). Diagnostic and statistical manual of mental disorders: DSM-IV-TR, 4th Edition Text Revision ed. Washington, DC: American Psychiatric Association.
22. Hsu CY, Huang CC, Chan WL, Huang PH, Chiang CH, et al. (2013) Angiotensin-receptor blockers and risk of Alzheimer's disease in hypertension population-a nationwide cohort study. Circ J 77: 405-410.
23. Biessels GJ, van der Heide LP, Kamal A, Bleys RL, Gispen WH (2002) Ageing and diabetes: implications for brain function. Eur J Pharmacol 441: 1-14. (Pubitemid 34465684)
24. Smith MA, Sayre LM, Monnier VM, Perry G (1995) Radical AGEing in Alzheimer's disease. Trends Neurosci 18: 172-176.
25. Gispen WH, Biessels GJ (2000) Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci 23: 542-549.
26. Ohara T, Doi Y, Ninomiya T, Hirakawa Y, Hata J, et al. (2011) Glucose tolerance status and risk of dementia in the community: the Hisayama study. Neurology 77: 1126-1134.
27. Zhao L, Teter B, Morihara T, Lim GP, Ambegaokar SS, et al. (2004) Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. J Neurosci 24: 11120-11126. (Pubitemid 40012971)
28. Craft S, Watson GS (2004) Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 3: 169-178. (Pubitemid 38229951)
29. Banks WA, Jaspan JB, Kastin AJ (1997) Selective, physiological transport of insulin across the blood-brain barrier: novel demonstration by species-specific radioimmunoassays. Peptides 18: 1257-1262. (Pubitemid 28026898)
30. Akter K, Lanza EA, Martin SA, Myronyuk N, Rua M, et al. (2011) Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? Br J Clin Pharmacol 71: 365-376.
31. Cholerton B, Baker LD, Craft S (2011) Insulin resistance and pathological brain ageing. Diabet Med 28: 1463-1475.
32. Gupta A, Bisht B, Dey CS (2011) Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. Neuropharmacology 60: 910-920.
33. Wu JH, Haan MN, Liang J, Ghosh D, Gonzalez HM, et al. (2003) Impact of antidiabetic medications on physical and cognitive functioning of older Mexican Americans with diabetes mellitus: a population-based cohort study. Ann Epidemiol 13: 369-376. (Pubitemid 36765399)
34. Beeri MS, Schmeidler J, Silverman JM, Gandy S, Wysocki M, et al. (2008) Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology. Neurology 71: 750-757.
35. de la Torre JC (2004) Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 3: 184-190.
36. Morris JC (1993) The clinical dementia rating (CDR): current version and scoring rules. Neurology 43: 2412-2414.
37. Bachman DL, Wolf PA, Linn R, Knoefel JE, Cobb J, et al. (1992) Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham study. Neurology 42: 115-119.